Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical TrialsYucai Wang, Michael Wang|JAMA Oncology|2019Cited by 829
Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 YearsNarjust Duma, Alex A. Adjei, Jesus Vera Aguilera et al.|Journal of Oncology Practice|2017Cited by 447
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell LymphomaMichael Wang, Nirav N. Shah, Koji Izutsu et al.|Journal of Clinical Oncology|2023Cited by 106
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN studyWilliam G. Wierda, Paolo Ghia, Nirav N. Shah et al.|The Lancet Haematology|2024Cited by 37
A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemiaPaul J. Hampel, Philip A. Thompson, Mahesh Swaminathan et al.|Blood Advances|2024Cited by 19